|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:ETV6-ITPR2 (FusionGDB2 ID:HG2120TG3709) |
Fusion Gene Summary for ETV6-ITPR2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: ETV6-ITPR2 | Fusion gene ID: hg2120tg3709 | Hgene | Tgene | Gene symbol | ETV6 | ITPR2 | Gene ID | 2120 | 3709 |
Gene name | ETS variant transcription factor 6 | inositol 1,4,5-trisphosphate receptor type 2 | |
Synonyms | TEL|TEL/ABL|THC5 | ANHD|CFAP48|INSP3R2|IP3R2 | |
Cytomap | ('ETV6')('ITPR2') 12p13.2 | 12p11.23 | |
Type of gene | protein-coding | protein-coding | |
Description | transcription factor ETV6ETS translocation variant 6ETS variant 6ETS-related protein Tel1TEL1 oncogeneets variant gene 6 (TEL oncogene) | inositol 1,4,5-trisphosphate receptor type 2IP3 receptorIP3R 2cilia and flagella associated protein 48type 2 InsP3 receptor | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | P41212 | Q14571 | |
Ensembl transtripts involved in fusion gene | ENST00000544715, ENST00000396373, | ||
Fusion gene scores | * DoF score | 59 X 37 X 25=54575 | 27 X 21 X 12=6804 |
# samples | 58 | 27 | |
** MAII score | log2(58/54575*10)=-6.55604351475058 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(27/6804*10)=-4.65535182861255 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ETV6 [Title/Abstract] AND ITPR2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | |||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ETV6 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 10514502 |
Tgene | ITPR2 | GO:0001666 | response to hypoxia | 19120137 |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerKB3 | . | . | ETV6 | chr12 | 11905513 | + | ITPR2 | chr12 | 26714885 | - |
Top |
Fusion Gene ORF analysis for ETV6-ITPR2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-3CDS | ENST00000544715 | ENST00000381340 | ETV6 | chr12 | 11905513 | + | ITPR2 | chr12 | 26714885 | - |
3UTR-intron | ENST00000544715 | ENST00000242737 | ETV6 | chr12 | 11905513 | + | ITPR2 | chr12 | 26714885 | - |
3UTR-intron | ENST00000544715 | ENST00000545902 | ETV6 | chr12 | 11905513 | + | ITPR2 | chr12 | 26714885 | - |
5CDS-intron | ENST00000396373 | ENST00000242737 | ETV6 | chr12 | 11905513 | + | ITPR2 | chr12 | 26714885 | - |
5CDS-intron | ENST00000396373 | ENST00000545902 | ETV6 | chr12 | 11905513 | + | ITPR2 | chr12 | 26714885 | - |
In-frame | ENST00000396373 | ENST00000381340 | ETV6 | chr12 | 11905513 | + | ITPR2 | chr12 | 26714885 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000396373 | ETV6 | chr12 | 11905513 | + | ENST00000381340 | ITPR2 | chr12 | 26714885 | - | 5901 | 437 | 274 | 3912 | 1212 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for ETV6-ITPR2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for ETV6-ITPR2 |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:/chr12:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ETV6 | ITPR2 |
FUNCTION: Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation. {ECO:0000269|PubMed:25581430}. | FUNCTION: Receptor for inositol 1,4,5-trisphosphate, a second messenger that mediates the release of intracellular calcium. This release is regulated by cAMP both dependently and independently of PKA (By similarity). {ECO:0000250|UniProtKB:Q9Z329}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for ETV6-ITPR2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>27723_27723_1_ETV6-ITPR2_ETV6_chr12_11905513_ENST00000396373_ITPR2_chr12_26714885_ENST00000381340_length(transcript)=5901nt_BP=437nt GCGTCCCGGGTCCCCGCGCCGCGCCGCGACCTGCAGACCCCGCCGCCGCGCTCGGGCCCGTCTCCCACGCCCCCGCCGCCCCGCGCGCCC AACTCCGCCGGCCGCCCCGCCCCGCCCCGCGCGCTCCAGACCCCCGGGGCGGCTGCCGGGAGAGATGCTGGAAGAAACTTCTTAAATGAC CGCGTCTGGCTGGCCGTGGAGCCTTTCTGGGTTGGGGAGAGGAAAGGAAAGTGGAAAAAACCTGAGAACTTCCTGATCTCTCTCGCTGTG AGACATGTCTGAGACTCCTGCTCAGTGTAGCATTAAGCAGGAACGAATTTCATATACACCTCCAGAGAGCCCAGTGCCGAGTTACGCTTC CTCGACGCCACTTCATGTTCCAGTGCCTCGAGCGCTCAGGATGGAGGAAGACTCGATCCGCCTGCCTGCGCACCTGCCAAAAAATCGTGG AATTGCCATTCCAGTGGATTTGGACAGCCAAGTTAATACTCTTTTCATGAAGAGCCATTCAAATATGGTGCAGAGAGCAGCAATGGGTTG GAGACTATCAGCTCGCTCTGGGCCACGCTTTAAGGAAGCTCTTGGAGGGCCTGCTTGGGATTACAGAAATATTATTGAAAAGTTACAGGA TGTAGTGGCCTCCTTGGAGCACCAGTTCAGCCCAATGATGCAGGCTGAATTCTCAGTGTTGGTTGATGTATTGTACAGTCCAGAACTGCT GTTCCCTGAGGGAAGCGATGCAAGAATAAGATGTGGCGCTTTCATGTCGAAGTTGATTAATCATACAAAGAAACTAATGGAGAAAGAAGA AAAACTGTGCATTAAAATTCTTCAGACATTACGAGAAATGTTAGAGAAGAAAGACAGCTTTGTGGAAGAGGGTAACACATTAAGAAAGAT ACTTCTGAATCGATACTTTAAAGGTGATTATAGTATTGGTGTGAATGGACACCTATCAGGAGCCTACTCCAAAACTGCACAGGTGGGAGG AAGCTTTTCTGGACAAGATTCAGATAAGATGGGGATATCAATGTCAGACATTCAGTGTCTGCTGGATAAAGAAGGTGCATCAGAACTTGT CATCGATGTTATAGTGAACACCAAAAATGACAGAATTTTTTCAGAAGGCATTTTCCTCGGCATTGCCTTGCTTGAAGGAGGAAATACACA AACACAGTATTCTTTCTACCAGCAGTTGCATGAACAAAAAAAGTCAGAAAAATTCTTTAAAGTTCTCTATGATCGAATGAAGGCTGCTCA GAAAGAAATAAGATCAACAGTGACAGTTAATACCATAGATTTAGGTAACAAAAAAAGGGACGATGACAATGAATTGATGACATCTGGTCC ACGAATGAGAGTAAGAGATTCAACACTACATTTAAAAGAGGGAATGAAAGGGCAATTAACAGAAGCTTCTTCAGCAACATCCAAAGCATA TTGTGTATACAGAAGAGAAATGGATCCAGAAATAGACATTATGTGCACAGGACCAGAAGCGGGAAACACTGAGGAAAAATCCGCAGAGGA AGTAACAATGAGTCCCGCAATTGCCATCATGCAGCCAATACTGAGATTTCTTCAGTTACTGTGTGAGAATCACAACCGGGAATTGCAGAA CTTCTTGAGGAATCAAAACAACAAAACAAATTACAACCTAGTCTGTGAGACCCTTCAGTTTCTGGACTGCATTTGTGGAAGTACAACCGG TGGCCTGGGCCTGTTGGGTCTCTACATCAATGAGAAGAATGTAGCGCTGGTCAACCAGAACCTGGAGAGCTTGACTGAGTATTGCCAGGG CCCTTGCCATGAAAATCAGACCTGTATCGCTACACATGAGTCTAATGGGATTGATATCATCATTGCTTTGATTCTGAATGACATAAACCC TCTTGGTAAATACCGAATGGACCTGGTGCTCCAGCTAAAGAACAATGCATCTAAACTTTTGCTGGCCATTATGGAAAGCAGACATGACAG TGAGAATGCAGAAAGAATTCTTTTTAACATGAGACCCAGAGAACTGGTGGATGTGATGAAGAATGCCTATAACCAAGGATTGGAATGTGA CCATGGGGATGATGAGGGTGGAGATGATGGTGTTTCTCCAAAAGATGTTGGACACAATATCTATATTCTGGCCCATCAGTTGGCCCGCCA CAATAAACTGTTGCAGCAGATGCTCAAACCAGGATCGGATCCAGATGAAGGAGATGAAGCCTTAAAGTATTATGCCAACCACACTGCACA GATTGAGATTGTCCGGCATGATAGGACCATGGAACAAATAGTTTTTCCTGTCCCCAATATATGTGAATACCTCACTCGAGAATCCAAGTG CCGTGTGTTCAATACAACTGAAAGGGATGAACAAGGAAGTAAAGTGAATGACTTTTTCCAGCAAACAGAAGATCTCTACAATGAAATGAA GTGGCAGAAGAAAATCAGGAATAACCCTGCACTGTTCTGGTTCTCGAGGCACATCTCTCTCTGGGGGAGCATTTCCTTCAACCTGGCTGT GTTCATCAATTTAGCTGTTGCTCTCTTCTACCCATTTGGGGATGATGGAGATGAAGGTACACTTTCTCCATTGTTCTCGGTTCTTCTTTG GATAGCAGTTGCGATCTGCACATCTATGCTGTTTTTCTTCTCCAAGCCTGTGGGTATTCGGCCGTTTCTTGTATCAATAATGCTCAGATC AATATATACAATAGGTCTTGGGCCTACATTAATACTTCTTGGTGCAGCTAATCTTTGTAATAAAATTGTTTTTCTGGTGAGTTTTGTTGG AAATCGTGGCACGTTCACCCGTGGGTACCGAGCAGTCATCCTGGATATGGCCTTTCTCTATCACGTGGCGTATGTCCTGGTTTGCATGCT GGGCCTTTTTGTCCATGAATTCTTCTATAGCTTCCTGCTTTTTGATTTGGTGTACAGGGAAGAGACTTTGCTGAATGTCATAAAAAGTGT CACACGAAATGGCCGCTCTATTATTCTAACTGCAGTCCTGGCTCTCATCCTCGTCTACCTGTTTTCCATTATTGGGTTCCTTTTTTTGAA GGATGACTTCACTATGGAAGTTGATAGGCTGAAAAACCGAACTCCTGTTACAGGCAGTCATCAAGTGCCTACTATGACTTTAACTACCAT GATGGAAGCATGTGCCAAGGAGAACTGTTCACCCACAATTCCAGCTTCAAATACAGCTGATGAAGAGTATGAAGATGGAATTGAAAGGAC GTGTGACACTCTCCTTATGTGCATTGTCACCGTGCTGAACCAGGGCCTCAGGAATGGCGGTGGTGTGGGGGATGTGCTAAGAAGGCCATC GAAAGATGAGCCCTTGTTTGCTGCCCGAGTGGTTTATGACCTTCTTTTTTATTTCATTGTTATCATTATTGTTCTGAACTTGATTTTTGG TGTTATCATCGATACTTTTGCTGATCTCAGAAGCGAAAAACAGAAAAAAGAAGAAATTCTAAAGACAACTTGTTTCATCTGTGGACTTGA GAGAGACAAGTTTGATAATAAAACGGTTTCATTTGAGGAGCACATTAAGTCAGAACACAATATGTGGCATTATTTGTACTTCATAGTCCT GGTGAAAGTTAAAGACCCAACAGAATACACTGGACCTGAAAGTTATGTGGCTCAAATGATTGTGGAGAAGAATTTGGATTGGTTTCCTCG GATGCGAGCCATGTCCCTCGTTAGCAATGAAGGCGACAGTGAGCAAAATGAAATTCGGAGCCTTCAGGAGAAGTTGGAATCGACCATGAG TCTGGTCAAACAGCTGTCGGGTCAGCTGGCGGAGCTCAAGGAGCAGATGACAGAACAAAGGAAGAATAAGCAGAGACTGGGCTTCCTCGG ATCAAACACACCCCATGTGAATCATCACATGCCACCACACTGATACCATGGGGGGAAGCCGTGACTAGCCTTTCATCAGTGTCCTGCCTG ATCACTGAATAAAGAACTGAGATGGAGGGGAGTGAACAGTGCCTATTGTTGAAAAGTTAAAAACAACCAAGTGCCAAGATGTTGAGTGGG TTAGCTCCGAGAACAATTTATAACTGTGTTTTCATGGTTGCGAAGACCTAACCTCAAATGCATCTGCTAGAAAGCGTACATCACACATTC GCAATGCATCAGGAAGAAAAGGCTTGCCCAAAAGGCTGGAGAGGGCAGGGAGCGGCAGGATGGAAGGAGACACGGGGCAGGGAGAACTCT CTTCTGCTAAATCGATAGGAGTCAGTTTTGTCTTAAATGCTGACTACAGCCACTGACATGGTTGGCTGGAATTTCTTTCTTTTAATTGTG GCATATAGGTTTGTGACACAAGAAGTCATACTTTGGTGGCTAAGTTTTACTAAGGAAAATAACTGAAAAGATTAAAAGTGAGAGCTGAAA AGAGAAATGATAATGCTTCCAAACTGTAGCTGTCACAGGGCAATTTCTTTATTTATAACATGAAGCACAATGGATTTACAGCTCTAGGAA CTTAGTACTTTGGAGCTTTTGCCTCTCACACTGACAACATAACAGGATGTGATTGCCTTCTCTGGGATTCAGACAGGCTCTGTCAATGTG GAGCACAAAAGGAGATTTTCATATAACTTGTTAAAAACATGTTCTAAGTCATGTATAGGCTAAGATTTTAAGAAGATCTGGGGGAATAAA AAGCCAACAGTAAGCCCCAGGAAAGGGTTTTTTGAGACCATATGTATGCTATTAAAATATATTGAGATTAATACATGAAAATGCTTAAAA GTGATAGGAATTATTGAGAAACTTATGATGGTGGCATTGCCTTTTATAAACATGGAGTGAAAGCCATTTGACTCAACGTTTGCTGTGCTT AAAGAATTGCTTCAGGACCCGAGCGTTTTTATGTATGCTGTTCCTGCAGTTAGGAAAAAAAAATCCAAGAAATGTATTGAATACTCAAGA AAATGCCACATTTCAATTACATATTTAAAACTGTATCTGTAAGGGCTTTTCAAAATGTAGCAAGATAAAAATCTCTTATTCAAATTGTTT TTGTATTAAATCATGCACTCAGAATTTGTCGAGGGAGAGAATAACCTGGTGTGTTCAGGTTATTCTTAGAGACTACACATTTGGAATAGC AGAGCAAAATATGGATAATGAAAGTGTTGGGAAAAAAGTGATGTGACAGGGAGTGAAGACACTTGATACCAGACTCTGGGAGATACTCTG CAAGTTGACCTGGCCTCTCCCCCACAGGAACAAAACACTGCCTCCAGAGTCTTTAAATTCTCAGTTATCAACGCCAAGGTTTAAGGTCTA GATAGGGTTTGCTATAGGGTTTGCTCTGACAATTTTTAAAGCTTTTGGATTGTTCTAACATAGCTTAAGCTATTGGTTCCTAAAAATCCC AAATCAAGATCTATGTAGAATATAAAGGAAGCCTGAACCAATCCTTCCACATACTGTTAAGATGTAGACTTGGAACAAAGCTGTTGGGAC CCAGAGCAATGAATTTTTGAACTGAAGCTACTGGTACTCCCCAGCACCACCTCATACTAAGAATTCCTCACTCTGACATGACAGTATTTT TTCTGACCAGGAGCTGAAAGACCCTGACATTCATGATCCAAAGATATAAGAAATTTTGATATGTCTGCATGCAGCACAGAACTTTGAACC TAGGAGGCAGTCAATAAATACATGAGAAATTCAGCTGTCATTCAGTTACTCTTAATTCTTTATAAAACTTTAAATGATACCACATATTTG TTTGTTTAAAATGGCTTTCCCAAAATCAAAGTAGACTAAAGCAGCCATCTTTAAAATCCAGGATCATCAATGCTATTAACAGTATCAGGT >27723_27723_1_ETV6-ITPR2_ETV6_chr12_11905513_ENST00000396373_ITPR2_chr12_26714885_ENST00000381340_length(amino acids)=1212AA_BP=55 MSETPAQCSIKQERISYTPPESPVPSYASSTPLHVPVPRALRMEEDSIRLPAHLPKNRGIAIPVDLDSQVNTLFMKSHSNMVQRAAMGWR LSARSGPRFKEALGGPAWDYRNIIEKLQDVVASLEHQFSPMMQAEFSVLVDVLYSPELLFPEGSDARIRCGAFMSKLINHTKKLMEKEEK LCIKILQTLREMLEKKDSFVEEGNTLRKILLNRYFKGDYSIGVNGHLSGAYSKTAQVGGSFSGQDSDKMGISMSDIQCLLDKEGASELVI DVIVNTKNDRIFSEGIFLGIALLEGGNTQTQYSFYQQLHEQKKSEKFFKVLYDRMKAAQKEIRSTVTVNTIDLGNKKRDDDNELMTSGPR MRVRDSTLHLKEGMKGQLTEASSATSKAYCVYRREMDPEIDIMCTGPEAGNTEEKSAEEVTMSPAIAIMQPILRFLQLLCENHNRELQNF LRNQNNKTNYNLVCETLQFLDCICGSTTGGLGLLGLYINEKNVALVNQNLESLTEYCQGPCHENQTCIATHESNGIDIIIALILNDINPL GKYRMDLVLQLKNNASKLLLAIMESRHDSENAERILFNMRPRELVDVMKNAYNQGLECDHGDDEGGDDGVSPKDVGHNIYILAHQLARHN KLLQQMLKPGSDPDEGDEALKYYANHTAQIEIVRHDRTMEQIVFPVPNICEYLTRESKCRVFNTTERDEQGSKVNDFFQQTEDLYNEMKW QKKIRNNPALFWFSRHISLWGSISFNLAVFINLAVALFYPFGDDGDEGTLSPLFSVLLWIAVAICTSMLFFFSKPVGIRPFLVSIMLRSI YTIGLGPTLILLGAANLCNKIVFLVSFVGNRGTFTRGYRAVILDMAFLYHVAYVLVCMLGLFVHEFFYSFLLFDLVYREETLLNVIKSVT RNGRSIILTAVLALILVYLFSIIGFLFLKDDFTMEVDRLKNRTPVTGSHQVPTMTLTTMMEACAKENCSPTIPASNTADEEYEDGIERTC DTLLMCIVTVLNQGLRNGGGVGDVLRRPSKDEPLFAARVVYDLLFYFIVIIIVLNLIFGVIIDTFADLRSEKQKKEEILKTTCFICGLER DKFDNKTVSFEEHIKSEHNMWHYLYFIVLVKVKDPTEYTGPESYVAQMIVEKNLDWFPRMRAMSLVSNEGDSEQNEIRSLQEKLESTMSL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ETV6-ITPR2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ETV6-ITPR2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ETV6-ITPR2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | ETV6 | C4015537 | THROMBOCYTOPENIA 5 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | ETV6 | C0023485 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | CTD_human |
Hgene | ETV6 | C0040034 | Thrombocytopenia | 3 | CTD_human;GENOMICS_ENGLAND |
Hgene | ETV6 | C0023480 | Leukemia, Myelomonocytic, Chronic | 2 | ORPHANET |
Hgene | ETV6 | C1332965 | Congenital Mesoblastic Nephroma | 2 | ORPHANET |
Hgene | ETV6 | C0006413 | Burkitt Lymphoma | 1 | ORPHANET |
Hgene | ETV6 | C0013146 | Drug abuse | 1 | CTD_human |
Hgene | ETV6 | C0013170 | Drug habituation | 1 | CTD_human |
Hgene | ETV6 | C0013222 | Drug Use Disorders | 1 | CTD_human |
Hgene | ETV6 | C0023452 | Childhood Acute Lymphoblastic Leukemia | 1 | CTD_human |
Hgene | ETV6 | C0023453 | L2 Acute Lymphoblastic Leukemia | 1 | CTD_human |
Hgene | ETV6 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CGI;CTD_human;GENOMICS_ENGLAND |
Hgene | ETV6 | C0029231 | Organic Mental Disorders, Substance-Induced | 1 | CTD_human |
Hgene | ETV6 | C0038580 | Substance Dependence | 1 | CTD_human |
Hgene | ETV6 | C0038586 | Substance Use Disorders | 1 | CTD_human |
Hgene | ETV6 | C0087031 | Juvenile-Onset Still Disease | 1 | CTD_human |
Hgene | ETV6 | C0236969 | Substance-Related Disorders | 1 | CTD_human |
Hgene | ETV6 | C0238463 | Papillary thyroid carcinoma | 1 | ORPHANET |
Hgene | ETV6 | C0376544 | Hematopoietic Neoplasms | 1 | CTD_human |
Hgene | ETV6 | C0376545 | Hematologic Neoplasms | 1 | CTD_human |
Hgene | ETV6 | C0740858 | Substance abuse problem | 1 | CTD_human |
Hgene | ETV6 | C1292769 | Precursor B-cell lymphoblastic leukemia | 1 | ORPHANET |
Hgene | ETV6 | C1510472 | Drug Dependence | 1 | CTD_human |
Hgene | ETV6 | C1832388 | Platelet Disorder, Familial, with Associated Myeloid Malignancy | 1 | ORPHANET |
Hgene | ETV6 | C1838656 | Macrocytosis, Familial | 1 | CTD_human |
Hgene | ETV6 | C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | CTD_human |
Hgene | ETV6 | C3495559 | Juvenile arthritis | 1 | CTD_human |
Hgene | ETV6 | C3714758 | Juvenile psoriatic arthritis | 1 | CTD_human |
Hgene | ETV6 | C4316881 | Prescription Drug Abuse | 1 | CTD_human |
Hgene | ETV6 | C4552091 | Polyarthritis, Juvenile, Rheumatoid Factor Negative | 1 | CTD_human |
Hgene | ETV6 | C4704862 | Polyarthritis, Juvenile, Rheumatoid Factor Positive | 1 | CTD_human |
Tgene | C0003132 | Anoxic Encephalopathy | 1 | CTD_human | |
Tgene | C0018800 | Cardiomegaly | 1 | CTD_human | |
Tgene | C0995195 | Anoxia of brain | 1 | CTD_human | |
Tgene | C1140716 | Hypoxic Brain Damage | 1 | CTD_human | |
Tgene | C1383860 | Cardiac Hypertrophy | 1 | CTD_human | |
Tgene | C1527348 | Brain Hypoxia | 1 | CTD_human | |
Tgene | C1862871 | ANHIDROSIS, ISOLATED, WITH NORMAL SWEAT GLANDS | 1 | CTD_human;ORPHANET;UNIPROT |